Bond.az White LogoBond.az Black Logo

Piper Sandler cuts e.l.f. Beauty target to $60

Piper Sandler cuts e.l.f. Beauty price target to $60 from $85, maintains Neutral rating. Stock trades at $53.23 near 52-week low.

Sebastian Young
BySebastian Young- Senior Editor
|
0

Piper Sandler lowered its price target on elf-beauty" class="internal-tag-link">e.l.f. Beauty shares (NYSE:ELF) to $60 from $85 while maintaining a Neutral rating on Monday.

The stock currently trades at $53.23, hovering just above its 52-week low of $52.78, with shares down 28% year-to-date.

According to Bond.az analysis, the stock appears undervalued at current levels, with Fair Value estimates suggesting potential upside.

The firm reduced its price target ahead of the company’s fourth-quarter fiscal 2026 earnings report scheduled for Tuesday morning. The focus will be on core Elf sales and the fiscal 2027 guidance.

Piper Sandler noted that e.l.f. Beauty will lap the disconnect between consumption and shipments in the second quarter of fiscal 2027. The company will also lap a $1 price increase starting August 1.

The rhode brand will face comparisons against its Sephora launch in early September, though the brand remains healthy and is scaling new distribution. Piper Sandler expects approximately 60% growth for rhode and sees potential upside from expansion into 19 new countries with Sephora Europe starting September.

Piper Sandler maintains below-consensus estimates for fiscal 2027 at $3.30 per share versus the Street estimate of $3.61.

More News
Today / 15:23
|
844

Legence Price Target Raised on AI Data Center Demand

Tigress Financial raises Legence price target to $125 on AI data center demand, citing record backlog and growth acceleration.

0
Today / 15:01
|
898

Truist Raises Acushnet Target to $97

Truist Securities boosts Acushnet price target to $97, citing healthy trends. Hold rating maintained. Read more on Bond.az.

0
Today / 15:00
|
738

Bill.com price target cut to $45 on take rate outlook

Truist Securities cuts Bill.com price target to $45 from $46, maintains Buy rating. Updated model reflects slower take rate expansion and cost-cutting measures.

0
Today / 14:53
|
873

Piper Sandler Reiterates Boston Scientific Buy Rating

Piper Sandler reiterated an Overweight rating on Boston Scientific. Agent DCB drives growth; stock undervalued per Bond.az.

0
Today / 14:52
|
436

Piper Sandler Reiterates Overweight on Climb Bio

Piper Sandler reiterates Overweight on Climb Bio. IgAN opportunity and CLYM116 outlook.

0
Today / 12:32
|
795

Morgan Stanley Reiterates Home Depot Rating on Execution

Morgan Stanley reiterates Overweight rating on Home Depot with $420 target, citing solid execution in a growthless housing market.

0
Today / 12:31
|
212

Compass Point Lowers DeFi Tech Target

Compass Point cuts DeFi Technologies price target to $1.45, maintains Buy rating amid bear market.

0
Today / 12:30
|
656

Benchmark Reiterates Baidu Stock Rating on AI Revenue Milestone

Benchmark reaffirms Buy rating on Baidu after AI revenue milestone. AI Cloud margins improve, new products launched.

0
Today / 12:04
|
952

Raymond James Backs Nutrien Stock on Potash

Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.

0
Today / 11:35
|
858

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 11:02
|
510

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

0
...